Real-world characteristics, treatment modifications, and outcomes for patients with Acute Myeloid Leukemia (AML) receiving hypomethylating agents (HMA) + venetoclax (VEN) as first-line treatment (1L)
Year: 2025
Type: conference-abstract
Source: Blood
Institutions: Yale University, Taiho Oncology (United States)
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417020962
Cites:
Cited by:
Related to: